Kornimate/medical-research-clean huggingface dataset:
serial echocardiography after subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage; Myocardial Stunning; Takotsubo Cardiomyopathy

Summary: there is increasing interest in myocardial abnormalities following central nervous system events, such as subarachnoid hemorrhage (sah). these cardiac abnormalities include ecg changes, decreased cardiac output, decreased blood pressure, specific cardiac enzyme elevations, and segmental wall motion abnormalities (swma). interestingly, wall motion abnormalities and ecg changes have shown to be reversible, and therefore the dysfunction has been described as neurogenic myocardial stunning. the pathophysiology of cardiac dysfunction following sah has not yet been fully elucidated. many reports (mainly case reports) have been published, but so far no study has investigated the frequency of these abnormalities in a prospective manner, have correlated the occurrence of the different cardiac abnormalities, and have assessed which clinical variables can predict cardiac dysfunction. and only a limited number of studies have related neurological outcome with cardiac dysfunction.

objectives: therefore, our study objectives are: 1) assessment of the frequency of myocardial dysfunction (segmental wall motion abnormalities, cardiac-specific enzyme elevations, and ecg changes) in patients with sah. 2) determination of predictive clinical variables for the occurrence of myocardial dysfunction following sah. 3) impact of myocardial dysfunction on neurological prognosis: death, secondary cerebral ischemia, hydrocephalus and rebleeding. methods: for this purpose serial echocardiograms and ecgs will be obtained and cardiac enzymes will be measured in 200-400 patients admitted to hospital with sah in the four participating centers. the clinical variables that will be studied to predict cardiac dysfunction are: medical history, the ct-scan score, circulatory parameters, blood samples, medication, surgical intervention (coiling or clipping), and the neurological condition (glasgow coma scale). the echocardiograms, ecgs and cardiac enzymes will be studied to determine if they have independent prognostic value for the outcome in sah patients. expected results: as ecg changes and drops in blood pressure are known to occur frequently, the researchers expect to find that cardiac contractile dysfunction in patients with sah occurs more frequently than is assumed now. moreover, if cardiac abnormalities have neurological prognostic significance further studies are needed for early recognition and treatment of the cardiac abnormalities in sah, a condition with a very poor prognosis.

Eligibility criteria:
inclusion criteria: * diagnosed with aneurysmal subarachnoid hemorrhage * admitted within 72 hours of the bleed exclusion criteria: * no informed consent * patients or patients' family unwillingness to participate

Keywords: subarachnoid hemorrhage takotsubo cardiomyopathy cardiac abnormalities outcome
audio-recorded vs. nurse-led brief mindfulness-based intervention

Conditions: Pain; Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: this is a single-site, three-arm, parallel-group randomized clinical trial (rct). the clinical effects of a nurse-led, very brief, preoperative mindfulness-based intervention for hip and knee replacement patients will be investigated relative to an audio-recorded very brief, preoperative mindfulness-based intervention delivered during the standard nurse consult and a nurse-led preoperative pain psychoeducation intervention during the standard nurse consult.


Eligibility criteria:
inclusion criteria: * 1) age ≥18, * 2) scheduled to undergo unilateral total knee or hip arthroplasty exclusion criteria: * 1) cognitive impairment preventing completion of study procedures. * 2) current cancer diagnosis, * 3) contralateral knee or hip replaced in the previous 3 months, * 4) intent to have contralateral knee or hip replaced or other, additional surgical procedure during the study period, * 5) intent to add new pain treatments during the study period (except for what is part of the study), * 6) other unstable illness judged by medical staff to interfere with study treatment.
validation of an innovative neonatal jaundice detection system (picterus) in indonesia

Conditions: Jaundice, Neonatal

Summary: the long-term goal of this project is to establish picterus as a permanent tool to detect nnj in the healthcare services of indonesia. offering early detection and therefore, timely treatment to nnj, will substantially improve neonatal health and directly work towards the sustainable development goal 3.2.2, reduce neonatal mortality. the study as the following specific subgoals: * demonstrate that picterus system performs accurately in indonesian newborns * ensure that picterus is in line with users' needs in indonesia

the long-term goal of this project is to establish picterus as a permanent tool to detect nnj in the healthcare services of indonesia. offering early detection and therefore, timely treatment to nnj, will substantially improve neonatal health and directly work towards the sustainable development goal 3.2.2, reduce neonatal mortality. the study as the following specific subgoals: * demonstrate that picterus system performs accurately in indonesian newborns * ensure that picterus is in line with users' needs in indonesia

Eligibility criteria:
inclusion criteria: - infants born with gestational age ≥37 weeks birth weight ≥2000g and ≤4500g age 1 - 14 days exclusion criteria: - infants transferred to the pediatric ward for advanced treatment. infants with a skin rash or other disease that affects the skin where measurements are performed. infants that receive or have received phototherapy in the last 24 hours. infants with an inborn disease
deep needling at zhongliao point to stimulate the sacral nerve for the treatment of slow transit constipation

Conditions: Constipation

Summary: clinical study on the treatment of colonic slow transit constipation by deep acupuncture at zhongliao point stimulating sacral nerve

1. observing the clinical efficacy of deep acupuncture at zhongliao point to stimulate the sacral nerve in the treatment of slow transit constipation of the colon through changes in main research indicators such as defecation frequency, stool shape, and fecal weakness. 2. clarify the technical focus and difficulties of deep needling at zhongliao point to stimulate the sacral nerve in the treatment of colonic slow transit constipation, providing a basis for guiding clinical promotion and treatment.

Eligibility criteria:
inclusion criteria: * meets the diagnostic criteria for slow transit constipation deficiency of both qi and yin; * age 18-65 years old; * i have not been treated with intestinal motility drugs in the past month. * those who have informed consent and voluntarily participate in signing an informed consent form, adhere to medical advice for treatment, and undergo regular follow-up visits. exclusion criteria: * other traditional chinese medicine syndrome differentiation types of constipation. * concomitant severe heart, lung, and kidney diseases, neurological diseases, and metabolic diseases; * discovering organic lesions such as colorectal cancer and colorectal hyperplasia through colonoscopy, abdominal pelvic ct, or barium enema; * patients with severe mental illness or mental illness or cognitive impairment. * children, pregnant women, lactating women, and pregnant women. * those who stop taking medication at will or use other medications on their own during treatment, do not follow medical advice for treatment, or have incomplete information that affects the judgment of results, safety, and efficacy. * have a history of abdominal surgery. * history of needle sickness. * people with a tendency to bleed.

Keywords: constipation
serrathor trial : interest of the novel serratus plane block in post operative analgesia after video-assisted thoracoscopic lobectomy

Conditions: Video Assisted Thoracoscopic Surgery; Lobectomy; Pain Post Operative; Regional Anesthesia

Summary: pain after thoracic surgery remains a challenge for anesthetists. although vats for lobectomy is associated with fewer complications compared to thoracotomy, pain after vats needs to be treated with opioids. opioids may lead to ponv, respiratory depression, sedation and pruritus. as part of multimodal analgesia and opioids sparing, several local regional techniques has been described: paravertebral block, thoracic epidural analgesia, intercostal block. to date, there is no gold standard for regional anesthesia after vats. serratus plane block is a local regional technique, recently described for analgesia after breast surgery and ribs fracture. in our hospital center, since 2016, we used the serratus plane block for patients scheduled for lobectomy vats : a local retrospective trial showed that spb was associated with a lower consumption of morphine. the purpose of this randomized controlled double blinded study is to evaluate the analgesic effect of the serratus plane block, added to a general anesthesia on post operative pain control after vats lobectomy.


Eligibility criteria:
inclusion criteria: * all patients undergoing lobectomy vats * older \> 18 years * patients who meet criteria of asa 1 to 3 class exclusion criteria: * patient's refusal to participate in the study * psychiatric disorder (impossibility to collect the informed consent) * patient under juridical protection * on going an other study * non balanced epilepsy * 3 grade auriculo-ventricular heart block without pacing * severe hepatocellular insufficiency * anti arrhythmic treatment : class iii of the vaughan william's classification * pregnant patient or/and breastfeeding * history of opioid abuse * allergy to local anesthetic drug or opioids

Keywords: serratus plane block analgesia after vats lobectomy vats
phenoxodiol in treating patients with refractory solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. purpose: phase i trial to study the effectiveness of phenoxodiol in treating patients who have refractory solid tumors.

objectives: * determine the maximum tolerated dose of phenoxodiol in patients with refractory solid tumors. * determine the steady-state pharmacokinetics of this drug in these patients. * determine the tumor response in patients treated with this drug. outline: this is a multicenter, dose-escalation study. patients receive phenoxodiol iv continuously over days 1-7. treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. cohorts of 3-6 patients receive escalating doses of phenoxodiol until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. patients are followed at 4 weeks. projected accrual: approximately 18-36 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed solid tumor * refractory to standard therapy or * no standard therapy exists * no breast cancer * no active cns metastases * known cns metastases must be previously treated with radiotherapy or surgery and stable for at least 4 weeks prior to study patient characteristics: age: * 18 and over performance status: * karnofsky 60-100% life expectancy: * at least 3 months hematopoietic: * platelet count greater than 100,000/mm\^3 * wbc greater than 3,000/mm\^3 * neutrophil count greater than 1,500/mm\^3 * hemoglobin greater than 10 g/dl (9 g/dl for women) hepatic: * bilirubin less than 1.2 mg/dl * transaminases no greater than 3 times upper limit of normal renal: * creatinine no greater than 1.4 mg/dl other: * no active infection * no contraindication to the insertion of a vascular access device * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * no concurrent systemic anticancer immunotherapy chemotherapy: * no concurrent systemic anticancer chemotherapy endocrine therapy: * no concurrent systemic anticancer hormonal therapy except luteinizing hormone-releasing hormone agonists or antagonists radiotherapy: * see disease characteristics * concurrent localized radiotherapy for control of local disease complications allowed surgery: * see disease characteristics other: * recovered from prior antineoplastic therapy * at least 4 weeks since prior investigational agents * no other concurrent investigational drugs

Keywords: unspecified adult solid tumor, protocol specific
vitamin k and bone turnover in postmenopausal women

Conditions: Osteoporosis

Summary: this one year study of the k vitamers phylloquinone (k1) and menatetranone (mk4) will study supplementation effects on bone turnover and bone density. women at least 5 years postmenopause with normal bone density who do not use estrogen therapy or the following medications may be eligible: alendronate (fosamax), risedronate (actonel), pamidronate (aredia), etidronate (didronel), zoledronate (zometa), teriparatide (forteo), raloxifene (evista), tamoxifene, warfarin (coumadin), anti-seizure medications, prednisone, or oral steroids. eligible subjects will take calcium and vitamin d (citracal) twice a day for the first two months and through-out the study. after the first two months, subjects are randomized to the k1, mk4 or placebo groups. return visits occur at 1, 3, 6 and 12 months. fasting blood and urine is collected at each visit and bone density is performed at 3 study visits.


Eligibility criteria:
* female, 5 years postmenopause. * ambulatory. * community dwelling. * able to ingest calcium and vitamin d supplements. * willing to restrict vitamin k intake. * stable thyroid dose if appropriate. * no history of hyperthyroidism, hyperparathyroidism or other metabolic bone diseases. * absence of hardware in hip and spine. * history of malignancy within the last five years. * not currently using coumadin or warfarin. * vitamin d supplements must be less than 800 iu daily. * have not used estrogen or other bone-altering medications (see list in study description) within the last year. * no history of liver disease or malabsorption. * no known allergy to vitamin k. * have not participated in an investigational drug trial within the last month.

Keywords: menopause vitamin k bone turnover bone density
randomized phase ii study of epirubicin vs caelyx in pretreated metastatic breast cancer

Conditions: Breast Cancer

Summary: doxorubicin is recognized as one of the most active drugs for breast cancer, but its clinical utility is limited because of a cumulative dose-dependent cardiac myopathy that can lead to potentially fatal congestive heart failure. caelyx (pegylated liposomal doxorubicin) was designed to reduce the cardiotoxicity of doxorubicin while preserving its antitumor efficacy

to compare the efficacy of pegylated liposomal doxorubicin versus epirubicin as second line chemotherapy in patient with advanced breast cancer

Eligibility criteria:
inclusion criteria: * age 18-75 years * eastern cooperative oncology group (ecog) performance status 0-2 * adequate bone marrow function (absolute neutrophil count \>1000/mm\^3, platelet count\>100000/mm\^3, hemoglobin\>9gr/mm\^3) * histologically- or cytologically- confirmed breast adenocarcinoma * no prior anthracycline-based chemotherapy as treatment of advanced breast cancer * no prior chemotherapy with ≥ 300mg/m2 doxorubicin or ≥ 540mg/m2 epirubicin as adjuvant setting * at least 4 weeks interval since prior anticancer treatment * measurable disease as defined by the presence of at least one measurable lesion(except bone metastases, ascites or pleural effusions) * life expectancy \> 3 months * written informed consent exclusion criteria: * pregnancy or nursing * documented history of congestive heart failure (chf), serious arrhythmia, or myocardial infarction (within 6 months) * other invasive malignancy except nonmelanoma skin cancer or acute infection. * radiation of measurable disease (except brain metastases) * progressive brain metastases according to clinical or radiological criteria. * brain metastases without prior radiation therapy

Keywords: advanced breast cancer pegylated liposomal doxorubicin epirubicin
neurostructural integration technique for fibromyalgia

Conditions: Fibromyalgia

Summary: fibromyalgia is a common cause of widespread musculoskeletal pain. the investigators have found that our patients seem to benefit from a soft tissue physical therapy called neurostructural integration therapy (nst). the purpose of this study was to compare nst to hydrotherapy which is already used to manage fibromyalgia symptoms.

twenty female patients who met the american college of rheumatology diagnostic criteria for the classification of fm were enrolled in the study. patients were randomly allocated to receive either hydrotherapy or nst. patient evaluations were performed at baseline, six weeks, three months, and six months. primary outcome measures included the sf-36 quality of life questionnaire, the fibromyalgia impact questionnaire and the total myalgic score. duration of morning stiffness and duration of weekly aerobic exercise as reported by the participants were secondary outcome measures. statistics analysis was performed by standard parametric and non parametric methods.

Eligibility criteria:
inclusion criteria: * any patient who fulfills acr diagnostic criteria for fibromyalgia exclusion criteria: * patients with established ischemic heart disease, uncontrolled hypertension or diabetes, hypothyroidism, severe depression

Keywords: fibromyalgia treatment physical therapy hydrotherapy
impact of nesiritide on early postoperative recovery after total cavo-pulmonary connection surgery in children

Conditions: Congenital Heart Disease; Total Cavo-pulmonary Connection

Summary: nesiritide, a recombinant human b-type natriuretic peptide, has favorable effects on patient symptoms, hemodynamics, and the neurohumoral profile in adults with decompensated congestive heart failure and in those recovering from cardiac surgery involving cardiopulmonary bypass. investigators seek to determine whether nesiritide would improve the early postoperative course after total cavo-pulmonary connection surgery in children.

objective: this study aims to evaluate the efficacy and safety of nesiritide after total cavo-pulmonary connection surgery in children. investigators hypothesized that compared with placebo, patients assigned to receive nesiritide will improve early postoperative outcomes. study design: the study is a a single-center, randomized, single-blinded, placebo-controlled, two-arm parallel-group clinical trial, patients undergoing total cavo-pulmonary connection surgery are assigned to receive nesiritide or placebo. a standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission. the primary outcome is days of chest drainage. secondary outcomes included days of hospitalization measures of cardiovascular function, renal function, and adverse events and neurohumoral. the eligible participants will be allocated into intervention and control groups in a 1:1 ratio randomly. the intervention group will receive study drug. all the participants will be followed up during hospitalization . statistical analysis: evaluation will be carried out on an intention-to-treat basis. values of analyzed endpoints between intervention group and control group will be compared according to the analysis plan.

Eligibility criteria:
inclusion criteria: 1. elective general anesthesia down fontan surgery patients, postoperative retention of patients with thoracic drainage tube 2. age ≤ 14 years old between hospitalized patients, men and women are not limited 3. postoperative hospital stay\> 7 days 4. patients or guardians voluntarily signed informed consent exclusion criteria: 1. before the group had serious head trauma need hospitalization or brain surgery patients 2. who received organ transplants 3. preoperative 48 hours application of recombinant b-type natriuretic peptide drugs 4. preoperative cardiogenic shock or hypotension difficult to correct the patient 5. preoperative patients with active arrhythmia 6. preoperative serum creatinine\> 1.5mg / dl or need dialysis patients 7. preoperative liver dysfunction (glutamic oxalacetic transaminase /glutamic pyruvate transaminase elevated normal high 3 times or more) 8. failed fontan patients requiring secondary surgery 9. patients with allergic to nesiritide 10. the researchers believe that should not participate in the entry of patients 11. 3 months before the trial participated in other clinical trials

Keywords: nesiritide total cavo-pulmonary connection congenital heart disease
pharmacokinetics, biodistribution, radiation dose and safety study of 68ga-nym032 in patients

Conditions: Prostate Cancer

Summary: 68ga-nym032 is a psma-targeting small-molecular radiotracer for pet/ct imaging of prostate cancer, which is needed for clinical trial to be conducted


Eligibility criteria:
inclusion criteria: 1. patients with pathologically confirmed prostate cancer; 2. age range from 18 to 75 years old (including 18 and 75 years old); 3. ecog score of 0 or 1; 4. expected life ≥ 6 months； 5. the subjects agree to take effective contraceptive measures during the study period and for at least three months after the diug administration; 6. the subjects are able to maintain good communication with the researchers；understand and follow the requirements of this study and sign an informed consent form before the start of relevant research operations. exclusion criteria: 1. known or suspected to be allergic to the investigational drug or any of its components; 2. accepting other investigational drugs upon enrollment, or within 5 biological half-lives of the drug at enrollment, or within 30 days after its last administration, whichever is longer; 3. those who have used any radioactive therapy medication within 90 days before investigational drug administration, or have received any radioactive diagnostic medication within 3 days before investigational drug administration; 4. planned androgen deprivation therapies use, any therapeutic intervention for the prostate cancer and use of folate supplements during the study; 5. plan to arrange surgery and other invasive interventions within 2 days after the injection of the investigational drug； 6. ongoing toxicity \>grade l from previous standard or investigational therapies； 7. patients with active infections during screening; 8. those who have no guarantee of being able to lie down quietly in the examination cabin during a pet examination, or those who suffer from claustrophobia and cannot cooperate in a pet examination: 9. other situations where the researchers believe that the subject is not suitable for inclusion in this study.